Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Public trust is key to a successful immunisation programme, writes Samantha Vanderslott in a piece for The Conversation.

Vaccination © Image by Angelo Esslinger from Pixabay

If you have been following the media coverage of the new vaccines in development for COVID-19, it will be clear that the stakes are high. Very few vaccine trials in history have attracted so much attention, perhaps since polio in the mid-20th century.

A now largely forgotten chapter, summer polio outbreaks invoked terror in parents. Today, restrictions on gatherings and movement in the efforts to control COVID-19 have been a huge strain on society, but in the 1950s, parents locked their children in stifling hot buildings during the summer with windows sealed shut because they were terrified polio would somehow seep through the cracks in the wall.

The development of the polio vaccine in the US in 1955 was a moment of global celebration. Reaching that point involved millions of citizens raising funds to develop the vaccine, political goodwill by the bucket-load and a driven public-private scientific collaboration, with scientist Jonas Salk at the helm. Children across the US were enlisted in one of the largest clinical trials in history.

Read the full article on The Conversation website, written by .

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Vaccine for TB receives a $1.5 million funding boost

The Oxford-run VALIDATE Network has received $1.5 million in funding for its tuberculosis vaccine work from the Bill & Melinda Gates Foundation.

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

Oxford Vaccine Group among winners at NHS Parliamentary awards

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.

New book highlights life-saving role vaccines play in prevention of killer diseases

'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.